Editorial: treating hepatorenal syndrome-a window and the views

Naaventhan Palaniyappan^{1

2}, Guruprasad Padur Aithal^{1

2}

Affiliations

¹ NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK.
² Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.

Editorial

Naaventhan Palaniyappan et al. Aliment Pharmacol Ther. 2020 Sep.

. 2020 Sep;52(5):895-896.

doi: 10.1111/apt.15943.

Naaventhan Palaniyappan^{1

2}, Guruprasad Padur Aithal^{1

2}

¹ NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK.
² Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.

No abstract available

Comment in

Editorial: treating hepatorenal syndrome-a window and the views. Authors' reply.
Allegretti AS, Jamil K, Moore K. Allegretti AS, et al. Aliment Pharmacol Ther. 2020 Sep;52(5):897. doi: 10.1111/apt.15981. Aliment Pharmacol Ther. 2020. PMID: 32852830 No abstract available.

Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.
Moore K, Jamil K, Verleger K, Luo L, Kebede N, Heisen M, Corman S, Leonardi R, Bakker R, Maï C, Shamseddine N, Huang X, Allegretti AS. Moore K, et al. Aliment Pharmacol Ther. 2020 Jul;52(2):351-358. doi: 10.1111/apt.15836. Epub 2020 Jun 4. Aliment Pharmacol Ther. 2020. PMID: 32495956 Free PMC article.

1. Schmidt ML, Sidney Barritt A, Orman ES, Hayashi PH Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology. 2015;148:967-U414.
1. Allegretti AS, Israelsen M, Krag A et al. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. Cochrane Database of Systematic Reviews. 20176(6):CD005162.
1. Israelsen M, Krag A, Allegretti AS et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9:CD011532.
1. Moore K, Jamil K, Verleger K, et al. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Aliment Pharmacol Ther. 2020; 52:351-358. https://doi.org/10.1111/apt.15836
1. Cavallin M, Piano S, Romano A et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983-992.